WoodTrust Financial Corp Makes New $1.14 Million Investment in ResMed Inc. (NYSE:RMD)

WoodTrust Financial Corp acquired a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 6,620 shares of the medical equipment provider's stock, valued at approximately $1,139,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RMD. Ossiam increased its stake in shares of ResMed by 2.4% in the 1st quarter. Ossiam now owns 1,919 shares of the medical equipment provider's stock valued at $420,000 after purchasing an additional 45 shares during the last quarter. Ascent Group LLC increased its stake in shares of ResMed by 2.3% in the 3rd quarter. Ascent Group LLC now owns 1,995 shares of the medical equipment provider's stock valued at $446,000 after purchasing an additional 45 shares during the last quarter. SeaCrest Wealth Management LLC increased its stake in shares of ResMed by 3.6% in the 4th quarter. SeaCrest Wealth Management LLC now owns 1,400 shares of the medical equipment provider's stock valued at $291,000 after purchasing an additional 48 shares during the last quarter. Capital Impact Advisors LLC increased its stake in shares of ResMed by 3.0% in the 4th quarter. Capital Impact Advisors LLC now owns 1,916 shares of the medical equipment provider's stock valued at $399,000 after purchasing an additional 56 shares during the last quarter. Finally, Dearborn Partners LLC increased its stake in shares of ResMed by 3.8% in the 3rd quarter. Dearborn Partners LLC now owns 1,577 shares of the medical equipment provider's stock valued at $344,000 after purchasing an additional 57 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ResMed

In other news, Director Peter C. Farrell sold 10,935 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the transaction, the director now directly owns 157,404 shares of the company's stock, valued at approximately $28,751,414.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Peter C. Farrell sold 10,935 shares of the business's stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the transaction, the director now directly owns 157,404 shares of the company's stock, valued at approximately $28,751,414.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Michael J. Rider sold 200 shares of the business's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $173.25, for a total value of $34,650.00. Following the completion of the transaction, the general counsel now directly owns 6,688 shares in the company, valued at $1,158,696. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,216 shares of company stock worth $2,046,617. Insiders own 1.21% of the company's stock.

ResMed Trading Up 0.9 %

Shares of NYSE RMD traded up $1.68 during trading on Wednesday, reaching $186.04. The company had a trading volume of 1,451,102 shares, compared to its average volume of 1,002,164. The company's fifty day moving average price is $186.80 and its 200-day moving average price is $166.98. ResMed Inc. has a 12 month low of $132.24 and a 12 month high of $243.52. The stock has a market cap of $27.36 billion, a P/E ratio of 30.75, a PEG ratio of 2.34 and a beta of 0.67. The company has a quick ratio of 1.89, a current ratio of 3.11 and a debt-to-equity ratio of 0.27.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 EPS for the quarter, beating analysts' consensus estimates of $1.81 by $0.07. ResMed had a return on equity of 23.86% and a net margin of 19.77%. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter in the previous year, the company posted $1.66 EPS. The business's revenue was up 12.5% on a year-over-year basis. As a group, research analysts expect that ResMed Inc. will post 7.45 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 14th. Shareholders of record on Thursday, February 8th were given a $0.48 dividend. The ex-dividend date was Wednesday, February 7th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 1.03%. ResMed's dividend payout ratio (DPR) is presently 31.74%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RMD shares. Oppenheimer lifted their price target on ResMed from $185.00 to $205.00 and gave the company an "outperform" rating in a research note on Tuesday, January 30th. Royal Bank of Canada lifted their price target on ResMed from $181.00 to $182.00 and gave the company a "sector perform" rating in a research note on Thursday, January 25th. JPMorgan Chase & Co. lifted their price target on ResMed from $160.00 to $195.00 and gave the company an "overweight" rating in a research note on Tuesday, January 9th. UBS Group boosted their price objective on ResMed from $175.00 to $180.00 and gave the stock a "neutral" rating in a research report on Thursday, January 25th. Finally, Needham & Company LLC boosted their price objective on ResMed from $215.00 to $224.00 and gave the stock a "buy" rating in a research report on Monday. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $199.20.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.